Celltrion Completes Application for FDA Approval of CT-P41, Biosimilar of Prolia® / Xgeva®

Start
On November 30, 2023, Celltrion announced that it filed for an abbreviated Biologics License Application (aBLA) for FDA approval of CT-P41 (denosumab), a proposed biosimilar of Amgen’s Prolia® / Xgeva® (denosumab)……
By: Venable LLP
Previous Story

Chinese Issuers See Progress on US Audit Issue and HKEX Reforms, but US Policies Could Impact Tech Companies

Next Story

Year-End Review – Data Privacy Insights To Take into 2024